Call Us: 1.800.873.5297


Testosterone Drugs Cause Heart Attacks, Strokes, and Blood Clots, New Lawsuits Claim

According to five lawsuits recently filed in the United States District Court for the Northern District of Illinois, the Testosterone replacement drug, AndroGel, is allegedly linked to causing serious medical problems, including life threatening heart attacks, strokes, and blood clots. The cases are Aurecchia v. AbbVie, Case No. 14-cv-00772; Benn v. AbbVie, Case No. 14-cv-00774; Gallagher v. AbbVie, Case No. 14-cv-00776; Marino v. AbbVie, Case No. 14-cv-00777; Myers v. AbbVie, Case No. 14-cv-00780.

AndroGel is a prescription drug manufactured by AbbVie Inc. and Abbott Laboratories. AndroGel has been heavily marketed to consumers and prescribers from 2010-2012 and the lawsuits allege “disease mongering” by engaging in “aggressive, award-winning direct-to-consumer and physician marketing and advertising campaigns” to alert men that they might be suffering from low testosterone. According to the allegations in the lawsuits, symptoms of low testosterone include being “sad or grumpy,” “experiencing deterioration in the ability to play sports,” and “falling asleep after dinner”, and though the most prevalent cause of these symptoms is the natural aging process, diagnoses of “Low T” have skyrocketed. This is consistent with the findings of a study published in March 2014 by the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism, which suggested that many men prescribed testosterone therapy have normal testosterone levels and do not meet treatment guidelines.

The five men bringing the lawsuits at issue were prescribed AndroGel for these types of symptoms, and now allege that AbbVie and Abbott concealed the known risks that the drug had a “serious propensity” to cause severe harm. According to the lawsuits, one man suffered a stroke caused by AndroGel, another experienced a mini-stroke, and three others suffered heart attacks.

New research suggests that testosterone replacement drugs such as AndroGel may increase the risk of heart attack, stroke and death. In November 2013, the Journal of the American Medical Association published a study finding that patients who underwent a coronary angiography, which is a procedure that uses X-ray imaging to view the heart’s arteries, were 29% more likely to suffer such medical problems if they were prescribed testosterone therapy.

Further, the FDA issued a Safety Announcement on January 31, 2014, announcing that it will investigate the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products.

The Pharmaceutical Litigation Department at Schlichter, Bogard & Denton, LLP represents clients nationwide who have suffered serious and fatal injuries as a result of dangerous pharmaceutical medications. At Schlichter, Bogard & Denton, LLP, we are committed to protecting the rights of persons injured by pharmaceutical companies.

The attorneys at Schlichter, Bogard & Denton, LLP are offering a free case review with no further obligation to those who allege to have suffered injuries after using testosterone therapy. If you believe you suffered injuries after using testosterone therapy, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.


The choice of a lawyer is an important decision and should not be based solely on advertisements. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.